Amgen touts new data for drug MariTide, moving rapidly into Phase 3 work

Am­gen said that an in­ter­im look at a Phase 2 tri­al of its an­ti-obe­si­ty drug Mar­i­Tide had left the com­pa­ny “very en­cour­aged,” and it planned to rapid­ly move for­ward with a fi­nal-stage pro­gram as well as boost man­u­fac­tur­ing ca­pac­i­ty for the ex­per­i­men­tal drug.

“We are con­fi­dent in Mar­i­Tide’s dif­fer­en­ti­at­ed pro­file and be­lieve it will ad­dress im­por­tant un­met med­ical need,” CEO Bob Brad­way said on a call Thurs­day with in­vestors af­ter Am­gen re­leased first-quar­ter re­sults. Brad­way said the com­pa­ny was plan­ning a broad Phase 3 pro­gram in obe­si­ty, di­a­betes and obe­si­ty-re­lat­ed con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.